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This is a series of cases describing the use of citalopram for the treatment of cataplexy in
patients with narcolepsy. Cataplexy is the most speciﬁc symptom of narcolepsy, being
characterized by a sudden and temporary loss of muscle tonus, triggered by episodes of
emotion during vigil.
Some antidepressants, besides gamma-hydroxybutyrate, are used for the control of
cataplexy. As gamma-hydroxybutyrate is not available in Brazil, local treatment is usually
done by the use of antidepressants.
Citalopram is a selective inhibitor of serotonin reuptake, with reasonable price and with
fewer side effects when compared with other drugs of the same type. In this study, we report
a series of cases with patients with narcolepsy and cataplexy, treated with citalopram for the
control of cataplexy.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cataplexy consists of a sudden and temporary loss of
muscle tonus, triggered by an emotional stimulus. It reaches
0–70% of all patients with narcolepsy and affects the indivi-
dual during vigil for some seconds to several minutes.
Normally, during the attack of cataplexy, there is no loss of
consciousness [1,2].ep. Production and Hosti
licenses/by-nc-nd/3.0/).
03-3.
Vila Clementino, CEP 040
(J. Castro).
an Association of Sleep.Cataplexy may affect only a speciﬁc muscle group or all
skeleton muscles. Besides, the episodes are more frequent
when the patients are sleepy of chronically stressed. As far as
event frequency, they might vary from sporadic during the
year, to several attacks during the day with important
incapacitation [1,3].
In this sense, the patients with cataplexy are deprived of
social situations to avoid emotions and subsequent attacks.ng by Elsevier B.V. This is an open access article under the CC BY-
20-060, São Paulo, SP, Brazil.
Table 1 – Anthropometric, clinical and drug usage data of
the narcoleptic patients with cataplexy.
Patients with cataplexy 74
Age (years) 30.1711.6
Gender (male) 39 (52.7%)
Corporal Mass Index (kg/m2) 25.44712.64
Hypnagogic/hypnopompic hallucinations 53 (71.6%)
Presence of HLA-DQB1*0602 44 (59.5%)
Average latency of SMLT 3.4773.19
SOREMPs 2.971.56
SMLT – Sleep Multiple Latencies Test; SOREMPs – quantity of REM
sleep episodes during SMLT.
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 5 0 – 5 2 51Therefore and due to this distancing of friends and familiar
interactions, there is a major prevalence of humor distur-
bances within this population [3].
The majority of stimulant medications used for the treat-
ment of diurnal excessive sleepiness is little effective upon
cataplexy or upon other symptoms related to the REM sleep
[4]. The pharmacological treatment of cataplexy in patients
with narcolepsy includes gamma-hydroxybutyrate, tricyclic
antidepressants, selective serotonin-reuptake inhibitors, ven-
lafaxine or reboxetine [5].
Although gamma-hydroxybutyrate is the main drug for
the treatment of cataplexy, this medication is still not avail-
able in Brazil [5]. Therefore, other options of treatment have
been used locally [1]. The objective of this article is to describe
our experience with the use of citalopram for the control of
cataplexy in a series of patients.2. Methods
We revised the ﬁles of 74 patients with clinical and electro-
physiological diagnostic of narcolepsy, according to the cri-
teria of the American Academy of Sleep Medicine (AASM), who
were treated by of Outpatient Facility for Diurnal Excessive
Sleepiness of the Federal University of São Paulo – Brazil [6].
All patients were treated between the years of 2008 and
2012, with an average periodicity of 4–6 visits per year. This
study was approved by the Ethical Committee for Research of
the Federal University of São Paulo (CEP 1802/07).
The continuous use of citalopram above six months, with
the total or partial control of cataplexy, was considered as a
therapeutic success after spontaneous report from the
patient. We have not used questionnaires or other objective
evaluation methods for cataplexy.
The proposed initial standard dosage for the control of
cataplexy was that of 20 mg/day. The side effects after the
use of citalopram were reported by the patients themselves
and were not obtained in a systemic way.3. Results
We evaluated 122 patients with the diagnostic of narcolepsy,
from which 74 (60.7%) demonstrated cataplexy (Table 1).
Citalopram was used for the control of cataplexy in 19
(25.7%) patients. From these 15 (78.9%) patients, citalopram
was the drug of ﬁrst choice and in 4 (21.1%) patients,
citalopram was the second or third choice for the control of
cataplexy. The control of cataplexy was achieved with a
dosage of 20 mg in 15 patients (78.9%) and the maximum
dosage was of 60 mg/daily.
The other antidepressants utilized by the patients were
ﬂuoxetine, sertraline and amytriptilin.
At the end of this study, the average period of citalopram
use was of a year and 2 months. Only one patient was
precociously discontinued, with less than a month of drug
treatment, due to the suspicion of weight gain associated
with the medication. Other 2 patients (13.3%) reported side
effects that resulted in drug substitution later on. All other
patients had good control of their cataplexy symptoms.4. Discussion
Actually, AASM also includes selective serotonin reuptake
inhibitors (SSRI) such as venlafaxine and reboxetine for the
treatment of cataplexy [1,4].
The mechanism of action of antidepressants upon cata-
plexy is still not fully understood; however, the regulation of
the cholinergic, serotonergic and adrenergic system is well
researched. The SSRI act much more selectively on seroto-
nergic receptors and do so in treating cataplexy. SSRI possess
much less side effects and less pronounced side effects than
the ones observed with the use of tricyclic antidepressants.
However, SSRI are also less efﬁcient in the control of cata-
plexy when compared with tricyclic antidepressants and to
selective noradrenergic reuptake inhibitors, being necessary
to increase the dosage to higher levels for the control of that
symptom [1].
Although tricyclic antidepressants were the ﬁrst choice of
medication used for the treatment of cataplexy, their admin-
istration is limited due to their strong anticholinergic side
effects, cardiac conduction disturbances, convulsive crisis,
sedation and constipation [8].
The chieﬂy SSRI used is ﬂuoxetine [8]. However, citalo-
pram possess the advantage of being a more serotonin-
selective inhibitor, with none or minimum effect upon other
drugs. The observed side effects of citalopram are generally
mild and transitory, being more frequent during the ﬁrst
weeks of treatment and reducing with its continuous usage in
normal dosage [9].
Even though there have been advances in the under-
standing of narcolepsy, there are still a few options for
treatment with reasonable success for cataplexy [7]. Although
with certain limitations, such as the retrospective manner
and the limited number of patients, this study conﬁrms the
usefulness and security of the use of Citalopram upon the
control of cataplexy in patients with narcolepsy. Controlled
studies must be performed to better characterize the beneﬁts
of such medications for the control of cataplexy.
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